GlassScriptPhysician profile
Parham A Mokri
NPI 1720036692
$5,111.56
in general payments reported to CMS, 2019-2025
24 companies · $16.79 in 2025
The $16.79 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $448 · 2021: $2,377 · 2022: $1,364 · 2023: $134 · 2024: $24.68 · 2025: $16.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $862.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $681.24 | 2019-2025 | Farxiga |
| Amgen INC. | $586.70 | 2019-2022 | |
| Daiichi Sankyo INC. | $414.11 | 2019-2022 | |
| Vifor Pharma, INC. | $406.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $334.16 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $310.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $232.23 | 2021-2023 | Benlysta |
| Akebia Therapeutics INC | $230.58 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $221.45 | 2019-2022 | |
| Horizon Therapeutics Plc | $177.88 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $174.09 | 2021-2022 | |
| Genzyme Corporation | $121.89 | 2019-2023 | |
| Opko Pharmaceuticals, LLC | $83.79 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $54.28 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $46.34 | 2022 | |
| Alnylam Pharmaceuticals INC. | $40.92 | 2021 | |
| Travere Therapeutics, INC. | $24.68 | 2024 | |
| Mallinckrodt Hospital Products INC. | $23.53 | 2020 | |
| Mallinckrodt Enterprises LLC | $21.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.65 | 2021 | |
| Genentech USA, INC. | $16.29 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.02 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parham Mokri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.